Leverage real-world data to drive brand success
Real-world data (RWD) is a critical asset in pharmaceutical innovation and research, enabling a deeper understanding of patients’ needs and driving the development of more effective therapies and personalised healthcare solutions. Leveraging direct access to patients and backed by over 70 million patient interactions across Europe over the past 30 years, Sciensus is uniquely positioned to uncover critical insights into patient experience and behaviour.
Our world-class expertise combined with a deep understanding of evidence requirements and industry leading digital solutions, can help you collect, generate, and communicate invaluable real-world evidence (RWE). This evidence underpins a wide range of activities, including securing market access, supporting regulatory submissions, optimising brand launches, conducting post-marketing safety studies and informing patient-level healthcare decision-making.
What is real-world data in healthcare?
Real-world data reveals how treatments perform in everyday clinical practice, drawing on data collected from actual patient care rather than controlled clinical trials. While traditional clinical trials take place in controlled research environments, RWD comes from diverse sources including electronic health records, insurance claims, disease registries, wearable devices and patients’ own reported experiences.
RWD is essential for demonstrating treatment value– ultimately leading to better patient outcomes and commercial success.
What’s the difference between real-world data and real-world evidence?
While real-world data refers to the raw unprocessed data collected from real-world sources, real-world evidence is generated from this data to answer or shed light on a specific research question.
Real-world evidence (RWE) transforms the RWD collected during routine patient care into powerful insights about a treatment’s effectiveness and safety across diverse patient populations, helping healthcare stakeholders make more informed decisions about long-term treatment approaches.
Benefits of real-world data collection for pharmaceutical companies
RWD helps show how drugs perform in real-world conditions, where patient adherence, comorbidities, and varying demographics play a role. Post-marketing surveillance helps detect rare or long-term adverse effects.
Understanding real-world effectiveness
RWD helps show how drugs perform in real-world conditions, where patient adherence, comorbidities, and varying demographics play a role. Post-marketing surveillance helps detect rare or long-term adverse effects.
Supporting regulatory decisions
By harnessing RWD, pharmaceutical companies can demonstrate the real-world effectiveness and cost-efficiency of their products, supporting new indications, formulations, or faster regulatory approvals.
Improving market access and reimbursement
RWD provides evidence for cost-effectiveness and value-based pricing which is critical for negotiations with payers. This can be especially helpful for high-cost drugs.
Sciensus’ unique solution
Sciensus, sitting at the intersection of patients and their medications, is uniquely positioned to draw on 30 years of patient interactions across Europe to generate this crucial insight. Every day we’re trusted to engage directly with patients, both in person and through digital solutions, enabling us to gather real-time, high-quality patient-reported data.
With data enriched by more than 70 million interactions, we uncover deep insight into the patient experience and adherence and persistence patterns across the entire treatment journey. Our expertise spans across cancer, rare and orphan diseases and long-term conditions, giving us a deep understanding of complex treatment regimens. We harness this expertise and insight to develop and deliver innovative patient interventions to support clinicians and pharmaceutical companies throughout the region to drive brand success and better outcomes for patients.
Our unique RWD proposition covers:
End-to-end study management
From observational to interventional and non-interventional studies, we expertly manage every stage of your research, ensuring high-quality results for regulatory submissions and publications.
Real-world evidence (RWE) insights
We deliver actionable evidence through robust data analytics, answering key research questions and supporting evidence generation for regulatory and clinical outcomes.
Post-market surveillance & pharmacovigilance
Our dedicated pharmacovigilance team monitors adverse events, ensuring continuous safety surveillance beyond market approval.
Longitudinal patient tracking
We provide a full patient journey view, enabling you to analyse persistence, adherence, and long-term outcomes to enhance treatment strategies.
Direct patient engagement
Our integrated digital platforms capture real-time, high-quality patient-reported data from patients cross Europe, offering insights into patient experiences and treatment impact.
Therapeutic expertise
With deep knowledge in oncology, rare diseases, and chronic conditions, we understand complex treatment regimens and the clinical context needed for accurate data interpretation.
Start transforming patient support today
Partner with Sciensus to develop a Digital+ PSP that drives better outcomes for your patients and demonstrates real-world treatment value. Contact our team to schedule a consultation.
Direct access to patients in their own homes
Seamless logistics and data integration
Comprehensive European network
Expertise that makes the difference
With our clinical expertise, primary source access to patients, experience and insights, no one knows patients like we do.
0
Years’ experience in Europe
0
Patients supported each year
0
Million direct patient interactions
0
Patients active on our apps
Meet our RWD expert
Learn more about how Real-World Data drives success
Through a collection of whitepapers, case studies, and expert insights, we showcase the power of data in shaping impactful, data-driven outcomes
